EMElisa Maria Maffioli

Elisa Maria Maffioli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisa Maria Maffioli has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is price associated with the quality of medicines? Evidence from active pharmaceutical ingredient testing in Nigeria

    by Marie Chantel Montás, Chimezie Anyakora, Elisa Maria Maffioli

    Determining the quality of medicines remains a challenge, particularly in low- and middle-income countries, where regulatory oversight and enforcement vary, and resources and infrastructure for quality testing are often constrained. In these settings, price is often used as a proxy for higher-quality medicines, yet empirical evidence supporting this assumption remains scarce. We conducted a mystery shopper survey in over 1,200 retail pharmacies across urban and rural areas in the six geopolitical zones of Nigeria, purchasing one drug sample from a list of twenty branded medicines, including analgesics, antimalarials, antibiotics, antihypertensives, and multivitamins. A sub-sample of the purchased medicines (N = 246) was tested for quality, defined as passing a laboratory test using High-Performance Liquid Chromatography (HPLC) to measure the Active Pharmaceutical Ingredient (API) content of each medicine. Using probit regressions, we examined the extent to which price is associated with quality, controlling for observable pharmacy and drug sample characteristics. A 1% increase in price is associated with a 16.7 percentage point increase in the probability of passing the laboratory test, conditional on other factors. Receiver Operating Characteristic (ROC) analysis shows strong out-of-sample classification performance, with an Area Under the Curve (AUC) of 0.82 for the price-only model, indicating that price alone explains much of the variation in quality. Other results show that medicines organized by brand and displaying visible expiration dates may signal higher quality, while the presence of other observable characteristics (e.g., packaging, storage, display) shows more counterintuitive associations with drug quality in this context. Stratified analyses show that the association between price and quality is particularly strong for analgesics and antibiotics. These findings suggest that price appears to be a reliable signal of medicine quality, whereas other characteristics of pharmacies and drug samples provide weaker and less consistent indicators. This underscores the need for stronger regulatory oversight, greater market transparency, and targeted consumer education to promote safer access to quality medicines.

  • Open Access

    Research capacity-building of midwives expanding access to safe abortion in the Democratic Republic of Congo: transnational research collaborations with civil society organizations

    by Kirsty M Bourret, Marie Chantal Kankolongo, Nadia Lobo, Jean-Claude Mulunda, Eva Åkerman, Elisa M Maffioli, Marie Klingberg-Allvin

    Enabling civil society organizations (CSOs) in sub-Saharan Africa to develop research ensures equitable scholarly representation and addresses local problems in sexual and reproductive health. To this end, a transnational research collaboration was formed to evaluate abortion services and develop the research capacity of two CSOs in the Democratic Republic of Congo (DRC). The team included Karolinska Institutet, Partners for Reproductive Justice (IPAS) and the National Midwives' Association (SCOSAF). The objective of this article is to discuss the context of the partnership, including research capacity-building inputs, processes, outputs, and outcomes, as well as lessons learned and recommendations. Activities were tailored to the research capacities of each CSO and the research team of clinical care providers over the two-year project period. Research capacity-building resulted in increased opportunities for team members to conduct research and manage research projects outside of academia. Overall, there were improvements in midwives' capacity to design and conduct research, and in the midwives' association's capacity for research management and project administration. Recommendations for others include pragmatic incorporation of gender considerations, approaches to organizational and individual research capacity-building, and baseline CSO capacity assessments for research management. Health research conducted in a non-academic setting, specifically within CSOs, can be a pathway to research equity. In DRC, it strengthened health professionals in their capacity to generate evidence to influence local abortion policy and health services in Kinshasa, DRC.


  • Open Access

    Substandard and falsified antibiotics are associated with antimicrobial resistance: a retrospective country-level analysis

    by Elisa M Maffioli, Yutong Lu, Chimezie Anyakora

    Objective: Substandard and falsified (SF) medicines pose a significant public health concern due to their elusive nature and potentially dire consequences, including the exacerbation of antimicrobial resistance (AMR). This study aims to quantitatively assess the relationship between the prevalence of SF antibiotics and AMR. Methods: We combine the Infectious Diseases Data Observatory database (1962–2019), with Global Bacterial Antimicrobial Resistance Burden Estimates (2019) to investigate whether the prevalence of SF antibiotics is positively associated with AMR. Using a quasi-binomial regression, we analyse 257 unique observations across 63 countries and 7 antibiotic classes between 1992 and 2019. We adjust the model for socioeconomic, environmental, health-related, governance and livestock production factors. Findings: We find that the prevalence of SF antibiotics is positively associated with AMR, after controlling for Gross Domestic Product per capita, population density, particulate matter 2.5, cardiovascular death rate, human antibiotic consumption, regulatory quality, livestock production. The prevalence of SF antibiotics is also positively associated with deaths per 100 000 people attributable to or associated with AMR. This is robust to adding more covariates and country fixed effects as well as dropping countries with a limited number of observations. Conclusion: AMR ranks among the top global health threats, presenting a multifaceted challenge affecting humans, animals and environment. This study sheds light on the possible relationship between SF antibiotics and AMR. While the prevalence of SF antibiotics appears to be associated with AMR, further research and more representative data are needed to determine the extent to which this association could be explained by a direct causal relationship.


  • Open Access

    Seasonal malaria chemoprevention in northern Mozambique: a cost-effectiveness analysis

    by Neide Canana, Ivan Alejandro Pulido Tarquino, Sónia Enosse, Kevin Baker, Maria Rodrigues, Christian Rassi, Akashdeep Singh Chauhan, Chuks Nnaji, Baltazar Candrinho, Elisa M. Maffioli

    Background: Malaria is endemic in Mozambique and one of the leading causes of death in children under 5 years old. In 2020 the country adopted the WHO-recommended seasonal malaria chemoprevention (SMC) strategy and delivered the intervention in all 23 districts of Nampula province between January and April 2023. The aim of this study is to estimate the cost-effectiveness of SMC in Nampula, Mozambique. Methods: Financial cost of implementing SMC were estimated from a limited health care provider perspective for the year 2023 in US$. Data on resource use of the SMC implementation was assessed from Malaria Consortium records. The number of eligible and treated children was collected from surveys after cycle 4. The number of malaria cases, deaths and Disability Adjusted Life-Years (DALYs) averted were estimated based on data from Global Burden of Disease 2019, Malaria Indicator Survey 2018, and National Malaria Control Programme. Incremental cost-effectiveness ratios (ICERs) were estimated, and sensitivity analyses were used to test the robustness of the ICERs. Results: The total financial cost of SMC implementation in Nampula province in 2023 was estimated to be $7,871,361.72. The study estimated a cost per targeted child of $6.05 and a cost per child who received full 3-day course of sulfadoxine-pyrimethamine in combination with amodiaquine (SPAQ) of $7.92. Furthermore, the cost per household with eligible children visited by a community distributor was $7.65; the cost per child who received day 1 SPAQ was $7.85 and the cost per child who received day 1 SPAQ by community distributor adhering to directly observed treatment was $8.50. In addition, the estimated cost was $93.50 per malaria case averted, $3286.59 per malaria death averted, and $130.16 per DALY averted. The ICERs were robust to a variety of alternative assumptions on costs and benefit estimates. Finally, $1,726,189.63 could have been saved if no ineligible children (60–119 months old) were treated through the programme. Conclusions: In line with existing evidence from other African countries, SMC is found to be cost-effective in Mozambique. SMC is a beneficial prevention strategy to improve under-five health in the country, at a relatively low-cost.


  • Open Access

    Allocation of Oral Cholera Vaccines in Africa

    by Elisa M. Maffioli, Yutong Lu

    Objectives: In this study, we examine the allocation of oral cholera vaccines (OCVs) across 25 African countries between 2013 and 2019. Methods: We constructed a dataset combining cholera outbreaks and requests, decisions, and deliveries of OCVs from the Global Task Force on Cholera Control, alongside additional covariates. Using machine learning algorithms, we assess the relative importance of socio-demographic, governance, and weather variables in predicting cholera outbreaks. We constructed and used an “index of cholera risk” as an instrumental variable to predict the likelihood of suspected cases and estimate the impact of cholera outbreaks on OCV allocation. Results: The majority of OCVs (77.4%) were allocated reactively. Governments took an average of 299.6 days to request doses, international agencies took 10.4 days to decide, and it took 84 days for vaccines to be delivered. Countries experiencing a cholera outbreak were 31.7 and 36.5 percentage points more likely to request and receive a vaccine delivery in the same month as the outbreak, respectively. We confirmed that the probability of obtaining vaccines through a reactive mechanism was 48.4 percentage points higher compared to preventive allocation. When exploring the heterogeneity of impacts, OCVs were more likely to be requested, allocated, and delivered in countries with strong institutions and those not facing crisis situations. OCVs were also more likely to be allocated in the central parts of the continent. Conclusions: While OCV allocation is responsive to cholera outbreaks, addressing delays, particularly in high-risk countries, could improve their distribution and mitigate the impact of cholera outbreaks. This study highlights the need for targeted strategies to ensure vaccine access in fragile and conflict-affected settings, where institutional capacity is weaker.


  • Open Access

    A comparative study between Near-Infrared (NIR) spectrometer and High-Performance Liquid Chromatography (HPLC) on the sensitivity and specificity

    by Elisa M. Maffioli, Chimezie Anyakora

    It is estimated that 10.5% of medicines in low- and middle-income countries are substandard or falsified (SF), causing approximately 1 million deaths annually. Over the past two decades, there have been significant technological advancements in low-cost, portable screening devices to detect poor-quality medicines, which could be especially beneficial in these countries. The pharmaceutical market in Nigeria is valued at USD 4.5 billion and is growing at over 9% annually. However, SF medicines remain a major public health concern. We compared a novel Near-Infrared (NIR) Spectrometer with high-performance liquid chromatography (HPLC) by analyzing 246 drug samples purchased from retail pharmacies across the six geopolitical regions of Nigeria. We measured the sensitivity and specificity of a patented and Artificial Intelligence (AI) - powered handheld NIR spectrometer, which uses a proprietary machine-learning algorithm as well as hardware and software, across four categories of medicines: analgesics, antimalarials, antibiotics, and antihypertensives. Our findings reveal that the prevalence of SF medicines remains high, with 25% of samples failing the HPLC test. When tested with the NIR spectrometer, only a smaller subset of medicines—specifically analgesics—failed the test. Sensitivity and specificity for all medicines were 11% and 74%, respectively. For analgesics, the sensitivity was 37%, and the specificity was 47%. While these devices hold great potential, regulators should require more independent evaluations of various drug formulations before implementing them in real-world settings. Improving the sensitivity of these devices should be prioritized to ensure that no SF medicines reach patients.


  • Can SMS interventions increase vaccination? Evidence from the COVID-19 pandemic in Kenya

    by Kevin Carney, Leah R. Rosenzweig, Wendy N. Wong, Florence Akech, James Otieno, Elisa M. Maffioli

  • Open Access

    Safe water treatment practices: A qualitative study on point-of-use chlorination in Nigeria

    by Ifeoma Idigbe, Michelle Cherian, Abideen O Salako, Babatunde Adewale, Babatunde L Salako, Elisa M Maffioli

    Approximately 2.2 billion people worldwide, about 25% of the world’s population, still do not have access to safely managed drinking water [1]. For those who live where large-scale investment in water infrastructure is lacking, point-of-use chlorination at the household level could be an alternative to realise the health benefits of safe drinking water [2]. Chlorination […]


  • Open Access

    A comparison between different models of delivering maternal cash transfers in Myanmar

    by Elisa M Maffioli, Nicholus Tint Zaw, Erica Field

    As part of a randomized controlled trial conducted in Myanmar between 2016 and 2019, we explore the performance of a maternal cash transfer program across villages assigned to different models of delivery (by government health workers vs loan agents of a non-governmental organization) and identify key factors of success. Measures include enrolment inclusion and exclusion errors, failures in payment delivery to enrolled beneficiaries (whether beneficiaries received any transfer, fraction of benefits received and whether there were delays and underpayment of benefit amounts) and whether beneficiaries remained in the program beyond eligibility. We find that women in villages where government health workers delivered cash transfers received on average two additional monthly transfers, were 19.7% more likely to receive payments on time and in-full and were 14.6% less likely to stay in the program beyond eligibility. With respect to the primary health objective of the program—child nutrition—we find that children whose mother received cash by government health workers were less likely to be chronically malnourished compared to those whose mother received cash by loan agents. Overall, the delivery of cash transfers to mothers of young children by government health workers outperforms the delivery by loan agents in rural Myanmar. Qualitative evidence suggests two key factors of success: (1) trusted presence and past interactions with targeted beneficiaries and complementarities between government health workers’ expertise and the program; and (2) performance incentives based on specific health objectives along with top-down monitoring. We cannot exclude that other incentives or intrinsic motivation also played a role.

  • Open Access

    Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries

    by Elisa M Maffioli, Marie C Montás, Chimezie Anyakora

    Substandard and falsified (SF) medicines still do not receive enough attention in public health. Substandard medicines are authorised medical products that fail to meet their quality standards or specifications, or both, due to within-factory errors or degradation in supply chains. Falsified medicines, instead, are defined as deliberately and fraudulently misrepresenting medicines’ identity, composition, or source […]